Ginkgo Bioworks Holdings Inc (NYSE:DNA) shares are surging Tuesday after the company announced the launch of its new protein large language model (LLM) built on Google Cloud.
What Happened: Ginkgo Bioworks has introduced a pair of new offerings aimed at making it easier for pharmaceutical and biotech companies to develop new medicines.
The company's protein large language model, built in collaboration with Alphabet Inc's (NASDAQ:GOOG) Google Cloud Consulting, will give individual researchers and enterprise companies the ability to develop medicines with insights from Ginkgo's private data.
"Ginkgo's new protein LLM and open API mark a major step forward in making advanced AI tools accessible for drug discovery and biological research," said Chris Sakalosky, vice president of strategic industries at Google Cloud.
Ginkgo Bioworks also announced the launch of its model API, designed to deliver biological AI models directly to machine learning scientists. The company noted that the new API is publicly available on its website as of Tuesday.
"I'm excited to see how the community builds on top of these models and our API. AA-0 is the first model we have released trained on Ginkgo's proprietary data – we're opening it to data scientists and bioinformaticians so they can build new models and applications on top," said Jason Kelly, CEO of Ginkgo Bioworks.
"We believe that the low cost for tokens and our other customer-friendly terms, like the lack of royalties, and our commitment to not re-use customer data, will allow users to build tools like iterative protein design programs that call our protein generation API or to use our embedding API to compute features for a clustering algorithm."
Ginkgo said it plans to roll out more models and expand API capabilities over the next year as it works towards building a robust suite of tools to help biotech and pharmaceutical companies solve complex problems.
DNA Price Action: Ginkgo Bioworks shares were up 16.7% at $7.26 at the time of publication, according to Benzinga Pro.
Ginkgo Bioworks Holdings Inc（纽约证券交易所代码：DNA）周二股价飙升，此前该公司宣布推出基于谷歌云的新蛋白质大语言模型（LLM）。
发生了什么：Ginkgo Bioworks推出了两款新产品，旨在使制药和生物技术公司更容易开发新药。
该公司与Alphabet Inc（纳斯达克股票代码：GOOG）谷歌云咨询公司合作建立的蛋白质大语言模型将使个体研究人员和企业公司能够根据银杏私人数据的见解开发药物。
谷歌云战略产业副总裁克里斯·萨卡洛斯基表示：“银杏的新蛋白质lLm和开放的API标志着在使先进的人工智能工具可用于药物发现和生物研究方面向前迈出了重要一步。”
Ginkgo Bioworks还宣布推出其模型API，旨在直接向机器学习科学家提供生物人工智能模型。该公司指出，新的API已于周二在其网站上公开发布。
“我很高兴看到社区如何建立在这些模型和我们的API之上。AA-0是我们发布的第一个基于Ginkgo专有数据训练的模型——我们正在向数据科学家和生物信息学家开放，这样他们就可以在此基础上构建新的模型和应用程序。” Ginkgo Bioworks首席执行官杰森·凯利说。
“我们相信，代币的低成本和我们的其他客户友好条款，例如缺乏特许权使用费，以及我们对不重复使用客户数据的承诺，将允许用户构建诸如调用我们的蛋白质生成API的迭代蛋白质设计程序之类的工具，或使用我们的嵌入式API来计算聚类算法的特征。”
Ginkgo表示，它计划在明年推出更多模型并扩大API能力，同时努力构建一套强大的工具来帮助生物技术和制药公司解决复杂的问题。
DNA价格走势：根据Benzinga Pro的数据，Ginkgo Bioworks的股价在发布时上涨了16.7％，至7.26美元。
